Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Recruiting

Phase 3

MarstacimabOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Sponsor:

Pfizer

Code:

NCT05145127

Conditions

Hemophilia A

Hemophilia B

Eligibility Criteria

Sex: Male

Age: 1 - 70+

Healthy Volunteers: Not accepted

Interventions

PF-06741086

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Pfizer on 2024-12-24.